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BUDGET IMPACT OF CHANGING ORAL ANTICOAGULANT PRESCRIBING TO PREVENT 
ATRIAL-FIBRILLATION-RELATED STROKE IN ENGLAND 
Orlowski A1, Jianhua Wu2, Julia Wilkins1, Wayne Smith1 
1Imperial College Health Partners, London, UK, 2University of Leeds, Leeds, UK 
OBJECTIVES: A difference-in differences (DiD) showed that prescription of direct oral 
anticoagulants (DOACs) increased substantially from 2011±2017, while stroke incidence 
decreased. A budget impact analysis to assess whether these changes affected costs associated 
with AF-related stroke prevention and care. METHODS: Data on AF-related stroke cases (stroke 
as primary diagnosis, AF as secondary diagnosis) for all clinical commissioning groups in 
England were obtained from Hospital Episode Statistics data (copyright NHS Digital 2018), 
prescribing data from the electronic Prescribing and Costing Tool, and AF detection and 
treatment data from the Quality and Outcomes Framework data, in the periods 2011±2013 and 
2015±2017. The per-patient health-care cost for the first year after a stroke (transport, scans, 
treatment, care, and rehabilitation) was set at £13,452. The estimated mean drug price for 
warfarin was £41.32 (excluding the costs of monitoring international normalisation ratio, as these 
data are not available in England), and for DOACs was £49.00±53.20 per pack. RESULTS: The 
volume of DOACs prescribed increased substantially between the two treatment periods and, 
accordingly, the total drug prescription costs for oral anticoagulants overall increased by 
£683,946,537 (983%). The total number of AF-adjusted strokes was reduced by 9,737 (13%) in 
2015±2017 versus 2011±2013, which led to a reduction in stroke-associated health-care costs of 
£130,982,124 (13%). Thus, overall the cost for oral anticoagulant prescribing and care after 
incident stroke increased by £552,964,413 (151%). CONCLUSIONS: The demonstrated 
Improvement in stroke prevention with increased DOAC prescribing, although being associated 
with 13% decrease in stroke incidence, led to nearly a tenfold rise in oral anticoagulant 
prescribing expenditure. With the likely rise in incidence of AF and AF-related stroke among 
(QJODQG¶Vageing population, these budget impact findings suggest that action is needed to 
achieve the most efficient use of NHS resources. 
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